Skip to main content
Premium Trial:

Request an Annual Quote

MIP Diagnostics: Michael Evans, Jim Reid

MIP Diagnostics has appointed Michael Evans, a non-executive chairman, as chairman of the board. Jim Reid has resigned from the position and plans to retire.

For 13 years, Evans was CEO of Oxford Gene Technology (OGT), where he led the company’s transformation from a licensing-led business model to a genomic products business before its sale to Sysmex in 2017. Before joining OGT, he held senior positions at GE Healthcare/Amersham Biosciences, including executive vice president, marketing and strategy, and executive vice president, corporate development. Evans previously served as managing director, fine chemicals at Ascot, has held several non-executive directorships, and was chairman of TAP Biosystems Group until its sale to Sartorius Stedim Biotech. He obtained a BA, MA, and DPhil in biochemistry from Oxford University and holds several non-executive positions including with Fluidic Analytics.